Wall St set for higher open after selloff on jobs data



(For a Reuters live blog on U.S., UK and European stock markets, click

or type LIVE/ in a news window)

* U.S. Senate approves bill on climate change, drug costs

* Tyson Foods down on quarterly profit miss

* Palantir drops on forecast cut

* Futures up: Dow 0.50%, S&P 0.62%, Nasdaq 0.77%

By Bansari Mayur Kamdar and Aniruddha Ghosh

Aug 8 (Reuters) - U.S. stock indexes were set to open higher on Monday after last week's blockbuster jobs data soothed some fears about an economic slowdown, but investors remained cautious as it also added to expectations of a hawkish Federal Reserve.

The focus this week will be on consumer prices data on Wednesday.

The S&P 500 has bounced back 13% from its mid-June lows, but investors fear that signs of persistent inflation this week could further bolster the Fed's case for aggressive monetary policy tightening.

"While it's clear the Fed needs to continue tightening policy, there are still about six weeks until the next meeting and we remind investors that economic data can change very quickly," said Robert Schein, chief investment officer, Blanke Schein Wealth Management.

"The CPI data will help to confirm if the Fed's tightening efforts have been successful in starting to tame inflation or if continued Fed tightening is needed."

U.S. rate futures have priced in a 68.5% chance of a 75-basis-point hike at the Fed's September meeting, up from about 41% before payrolls data on Friday beat market expectations.

Banks that tend to benefit from a higher interest rate environment extended their gains in trading before the bell.

Megacap growth and technology stocks edged higher, with Tesla TSLA.O up 2.3%. The U.S. electric-car maker signed contracts worth about $5 billion to buy materials for their batteries from nickel processing companies in Indonesia, according to a CNBC report.

Other high-growth stocks such as Apple Inc AAPL.O and Amazon.com Inc AMZN.O gained as U.S. Treasury yields pulled back from sharp highs in the previous session. The benchmark 10-year yield declined 1.6% in early trading.

Meanwhile, the U.S. Senate on Sunday passed a sweeping $430 billion bill intended to fight climate change, lower drug prices and raise some corporate taxes.

"All in all, it's a net positive. Biotech and pharma should rebound after some uncertainty because it (the bill) is less onerous than initially anticipated as it relates to negotiating drug prices," said Thomas Hayes, managing member, Great Hill Capital LLC, New York.

Hayes added that a lot of companies might accelerate their stock buybacks as they now have incentive to aggressively initiate buybacks before the 1% tax kicks in, helping the equity markets overall.

Nvidia Corp NVDA.O fell 7% on saying it expects second-quarter revenue of about $6.70 billion, down 19% from the prior quarter, largely hurt by weakness in its gaming business.

Signify Health Inc SGFY.N jumped 15.1% on a media report that CVS Health Corp CVS.N was looking to buy the health technology company.

Global Blood Therapeutics climbed 4.6% on Pfizer's PFE.N $5.4 billion deal for the blood disorder drugmaker.

At 08:50 a.m. ET, Dow e-minis 1YMcv1 were up 164 points, or 0.50%, S&P 500 e-minis EScv1 were up 25.75 points, or 0.62%, and Nasdaq 100 e-minis NQcv1 were up 102.25 points, or 0.77%.

Palantir Technologies Inc PLTR.N dropped 14.1% after the data analytics software company lowered its annual revenue forecast as the timing of some large government contracts remained uncertain.

Tyson Foods Inc TSN.N fell 3.4% on missing quarterly profit expectations.
Reporting by Bansari Mayur Kamdar and Aniruddha Ghosh in Bengaluru; Editing by Shounak Dasgupta

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明